<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909359</url>
  </required_header>
  <id_info>
    <org_study_id>20150750</org_study_id>
    <secondary_id>VEDO-IISR-2014-100892</secondary_id>
    <nct_id>NCT04909359</nct_id>
  </id_info>
  <brief_title>Characterization of CD Responders to Vedolizumab</brief_title>
  <official_title>Immunophenotypic Characterization of Crohn's Disease (CD) Responders to Vedolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize which patients with Crohn's disease are likely&#xD;
      to respond to standard of care to vedolizumab therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Actual">May 18, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T cell concentration</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>Evaluated from peripheral blood samples and lamina propria biopsies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effector memory T cells concentration</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>Evaluated from peripheral blood samples and lamina propria biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T regulatory cells concentration</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>Evaluated from peripheral blood samples and lamina propria biopsies</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Crohn's disease (CD)</arm_group_label>
    <description>People with CD recently receiving vedolizumab as standard of care will be followed up to 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis (UC)</arm_group_label>
    <description>People with UC recently receiving vedolizumab as standard of care will be followed up to 5 years.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants being seen at the University of Miami IBD clinics with a diagnosis of CD or UC&#xD;
        and about to initiate standard of care treatment with vedolizumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or Female ≥18 and ≤70 years old.&#xD;
&#xD;
          2. Patients must be appropriate for baseline colonoscopy prior to induction therapy with&#xD;
             vedolizumab.&#xD;
&#xD;
          3. Patients must have active inflammatory disease as seen by colonoscopy. 3A-Adult&#xD;
             patients with moderately to severely active UC who have:&#xD;
&#xD;
               1. had an inadequate response with, lost response to, or were;&#xD;
&#xD;
               2. intolerant to a tumor necrosis factor (TNF) blocker or;&#xD;
&#xD;
               3. immunomodulator; or had an inadequate response with, were;&#xD;
&#xD;
               4. intolerant to, or demonstrated dependence on corticosteroids:&#xD;
&#xD;
                    -  inducing and maintaining clinical response&#xD;
&#xD;
                    -  inducing and maintaining clinical remission&#xD;
&#xD;
                    -  improving endoscopic appearance of the mucosa&#xD;
&#xD;
                    -  achieving corticosteroid-free remission 3B-Adult patients with moderately to&#xD;
                       severely active CD who have&#xD;
&#xD;
               1. had an inadequate response with, lost response to, or were&#xD;
&#xD;
               2. intolerant to a TNF blocker or immunomodulator; or had an&#xD;
&#xD;
               3. inadequate response with, were intolerant to, or demonstrated&#xD;
&#xD;
               4. dependence on corticosteroids:&#xD;
&#xD;
                    -  achieving clinical response&#xD;
&#xD;
                    -  achieving clinical remission&#xD;
&#xD;
                    -  achieving corticosteroid-free remission&#xD;
&#xD;
          4. Patients will also have biochemical analysis with CRP and fecal calprotectin prior to&#xD;
             initiating treatment with vedolizumab.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients that will not undergo colonoscopy at baseline prior to treatment with&#xD;
             vedolizumab.&#xD;
&#xD;
          2. Patients who do not have endoscopic or biochemical (CRP, calprotectin) evidence of&#xD;
             inflammation.&#xD;
&#xD;
          3. Patients that have been on natalizumab within 12 weeks of beginning vedolizumab.&#xD;
&#xD;
          4. Previous treatment with cyclosporine, thalidomide, or investigational drugs within 30&#xD;
             days of enrollment, prior treatment with vedolizumab&#xD;
&#xD;
          5. Toxic megacolon&#xD;
&#xD;
          6. Abdominal abscess&#xD;
&#xD;
          7. Symptomatic colonic stricture&#xD;
&#xD;
          8. Stoma&#xD;
&#xD;
          9. Increased risk of infection (eg, active or latent tuberculosis, immunodeficiency)&#xD;
             Other clinically meaningful laboratory abnormalities: pregnancy or lactation, an&#xD;
             unstable or uncontrolled medical disorder, colonic dysplasia or adenomas, and&#xD;
             malignant neoplasms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria T Abreu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Maria Abreu</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease (IBD)</keyword>
  <keyword>IBD</keyword>
  <keyword>CD</keyword>
  <keyword>UC</keyword>
  <keyword>Vedolizumab</keyword>
  <keyword>VDZ</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

